All In Biotech

Drug Trial Radar · NCT06194201

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

A Multi-centre, Randomized, Double-blind, Active Controlled, Parallel Groups, Phase II Study to Evaluate the Efficacy and Safety of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

61

Actual

Start

Apr 27, 2024

Primary completion

Nov 7, 2025

Study completion Nov 7, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS9432 in patients with candidemia and/or invasive candidiasis

Conditions

  • Patients With Candidemia and/or Invasive Candidiasis

Interventions

  • HRS9432Drug

    Dosing frequency: intravenously once week

  • Caspofungin Acetate for InjectionDrug

    Dosing frequency: D1 70mg,followed by 50mg intravenously once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate overall success (mycological eradication and resolution of systemic signs attributable to candidemia and/or invasive candidiasis [IC]) of HRS9432 IV in subjects with candidemia and/or IC in the Microbiological Intent-to-treat (mITT) populationTime frame: Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital Of University Of South China

    Hengyang, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.